Sumatriptan Succinate Pharmaceutical API
Pharmaceutical Premium
Pharmaceutical API

Sumatriptan Succinate

High-purity pharmaceutical grade Sumatriptan Succinate API manufactured to meet stringent USP/EP specifications for migraine medication production. Our pharmaceutical-grade Sumatriptan Succinate delivers exceptional quality and consistency for critical pharmaceutical applications.

  • USP/EP Compliant Grade
  • High Purity (>99.5%)
  • Triptan Antimigraine Agent
  • GMP Certified Manufacturing
  • Reliable Supply Chain
  • Complete Documentation
Request Quote Technical Support

Technical Specifications

Chemical Formula: C14H21N3O2S·C4H6O4
CAS Number: 103628-48-4
Molecular Weight: 413.49 g/mol
Physical State: White to off-white crystalline powder
Purity (HPLC): ≥99.5% (USP/EP Grade)
pH (1% solution): 4.5-6.0
Loss on Drying: ≤0.5%
Residue on Ignition: ≤0.1%
Heavy Metals (as Pb): ≤10 ppm
Related Substances: ≤0.5% (total impurities)
Melting Point: 166-170°C
Solubility: Freely soluble in water
Storage Conditions: Store at room temperature, protect from light
Shelf Life: 3 years from date of manufacture
Packaging Options: 25g, 50g, 100g pharmaceutical containers

Applications

Oral Tablet Formulations
Injectable Formulations
Migraine Treatment
Cluster Headache Relief
Triptan Therapy
Emergency Medicine
5-HT1 Receptor Agonist
Neurology Applications
Neurological Research
Clinical Neurology
Regulatory Submissions
Reference Standards

Industry-Specific Grades

DRAVYOM offers specialized Sumatriptan Succinate grades tailored for specific neurological pharmaceutical requirements, ensuring optimal performance and regulatory compliance across diverse migraine treatment therapeutic applications.

USP Grade (United States Pharmacopeia)
Purity: ≥99.5% (HPLC) Related Substances: ≤0.5% Heavy Metals: ≤10 ppm Application: FDA-compliant formulations
EP Grade (European Pharmacopoeia)
Purity: ≥99.5% (HPLC) pH: 4.5-6.0 (1% solution) Loss on Drying: ≤0.5% Application: EU regulatory submissions
Neurological Grade
Purity: ≥99.8% (HPLC) CNS Activity: Verified Endotoxin: ≤0.25 EU/mg Application: Migraine therapy
Injectable Grade
Purity: ≥99.9% (HPLC) Sterility: Compliant Particulate Matter: <25 µm Application: Injectable formulations

Quality Standards

DRAVYOM's Sumatriptan Succinate is manufactured under stringent quality control protocols, meeting international pharmaceutical standards including USP, EP specifications. Our neurological-grade production ensures consistent performance and regulatory compliance.

ISO 9001:2015 Certified Manufacturing
USP/EP Grade Specifications
≥99.5% HPLC Purity
Advanced Neurological Testing
Triptan Therapy Grade
Batch-to-Batch Consistency
Comprehensive COA
Pharmaceutical Grade Packaging

Advanced Chemical Properties & Performance

Sumatriptan Succinate exhibits exceptional serotonin receptor agonist properties essential for neurological applications. Its ultra-pure composition and precise molecular structure ensure reliable performance in demanding migraine treatment formulations.

Molecular Properties
Molecular Weight: 413.49 g/mol
LogP: 1.2
pKa: 9.6
Bioavailability: 14%
Physical Properties
Melting Point: 165-170°C
Solubility (Water): 37 mg/mL
Crystalline Form: Stable succinate salt
Hygroscopicity: Non-hygroscopic
Pharmaceutical Performance
5-HT1D Receptor Ki: 2.3 nM
5-HT1B Receptor Ki: 17 nM
Selectivity: Triptan selective
Stability: Stable in solid state
Purity Specifications
Assay: ≥99.0%
Related Substances: ≤0.5%
Heavy Metals: ≤10 ppm
Residual Solvents: ICH Q3C compliant
Stability Properties
Shelf Life: 5 years (unopened)
Light Sensitivity: Protect from light
Temperature Stability: Stable at room temperature
pH Stability: Stable pH 4-7

Performance Characteristics

Detailed performance metrics demonstrate Sumatriptan Succinate superiority in migraine applications with exceptional serotonin receptor binding, neurological activity, and reproducibility across diverse triptan formulations.

Receptor Binding

Ki: 2.3 nM (5-HT1D), 17 nM (5-HT1B)

High-affinity serotonin binding
Bioavailability

Oral: 14% absolute bioavailability

Rapid CNS penetration
Stability

Solid state: >5 years stability

Long-term pharmaceutical integrity
Thermal Stability

Working range: 15-40°C processing

Stable during formulation
Batch Reproducibility

Variation: ±0.5% between batches

Consistent lot-to-lot performance
Shelf Stability

5 years under proper storage conditions

Extended pharmaceutical grade integrity

Safety Information

Pharmaceutical grade neurological API requiring careful handling. Handle with appropriate protective equipment in controlled environments. Avoid skin contact and inhalation. Follow cGMP guidelines for neurological APIs and ensure proper waste disposal procedures.

Pharmaceutical API
Avoid Skin Contact
Avoid Inhalation

Storage & Handling

Store in original sealed containers in a cool, dry, well-ventilated area away from light and moisture. Keep containers tightly closed and protect from direct sunlight. Use appropriate containment measures for pharmaceutical API handling.

Cool storage (2-8°C)
Protect from light
Original sealed containers
Pharmaceutical containment required

Chemical Mechanisms & Reaction Pathways

Sumatriptan Succinate exhibits specific serotonin receptor agonist mechanisms essential for migraine and cluster headache therapeutic applications. Its molecular structure enables selective 5-HT1B/1D receptor activation with predictable neurological therapeutic responses.

Receptor Agonism

Selective 5-HT1B/1D serotonin receptor agonist activity

Vasoconstriction mechanism
Neurological Targeting

Cranial vessel constriction and neuropeptide release inhibition

Migraine relief
Bioavailability

Optimized pharmaceutical formulation for rapid onset

Enhanced therapeutic efficacy
Selectivity

Selective targeting minimizes cardiovascular side effects

Improved safety profile

Regulatory Compliance & Documentation

Comprehensive regulatory compliance ensures global pharmaceutical access with complete documentation packages supporting international drug development and manufacturing standards.

USP Specifications

United States Pharmacopeia pharmaceutical standards compliance

EP Standards

European Pharmacopoeia specifications for pharmaceutical quality

ICH Guidelines

International Conference on Harmonization standards compliance

GMP Certification

Good Manufacturing Practices certified production facility

DMF Support

Drug Master File documentation for regulatory submissions

CEP Available

Certificate of Suitability to European Pharmacopoeia monographs

Technical Support & Value-Added Services

DRAVYOM's pharmaceutical development team provides comprehensive formulation support, regulatory assistance, and technical services to optimize pharmaceutical performance in your specific drug development applications.

Formulation Development
  • Dosage form optimization support
  • Stability testing guidance
  • Bioavailability enhancement
  • Custom formulation development
Analytical Services
  • Method development and validation
  • Impurity profiling and identification
  • Stability indicating methods
  • Dissolution testing support
Regulatory Support
  • Regulatory submission assistance
  • DMF preparation and maintenance
  • Pharmacovigilance support
  • Global registration strategy
Supply Solutions
  • Pharmaceutical supply chain management
  • Cold chain logistics
  • Custom packaging solutions
  • Global distribution network

Environmental Impact & Sustainability

Our pharmaceutical production emphasizes environmental responsibility through sustainable manufacturing practices, green chemistry principles, and comprehensive environmental impact management for pharmaceutical operations.

Green Chemistry

Sustainable synthetic routes with minimal environmental impact

Water Management

Advanced wastewater treatment and recycling systems

Clean Production

Energy-efficient synthesis with emission controls

Safe Disposal

Comprehensive pharmaceutical waste management protocols

ISO 14001

Environmental management system certified production

Sustainable Packaging

Recyclable pharmaceutical packaging solutions

Manufacturing Excellence & Quality Control

DRAVYOM's state-of-the-art pharmaceutical manufacturing facility employs advanced synthesis technology and continuous monitoring systems to ensure consistent pharmaceutical quality and performance across all production batches.

Production Process

Advanced synthesis and purification in GMP-controlled clean-room environment

Multi-stage purification for pharmaceutical grade quality
Quality Testing

Comprehensive testing protocol including purity, potency, and impurity profiling

HPLC, GC-MS, and spectroscopic analysis
Quality Systems

ISO 9001:2015 and GMP quality management systems

Continuous improvement and validation protocols
Packaging Control

Pharmaceutical-grade packaging with controlled atmosphere

Contamination prevention and stability protection

Market Applications & Performance Data

Comprehensive pharmaceutical development data demonstrating effectiveness across diverse therapeutic applications with quantified performance metrics and clinical validation support.

Pharmaceutical Development
Formulation Success: 95+ formulations developed Regulatory Approvals: 100+ successful submissions Quality Consistency: 99.9% batch compliance
Research Applications
Clinical Studies: 200+ supported trials Publication Support: 150+ peer-reviewed papers Innovation: Custom API development
Commercial Manufacturing
Scale-up Success: 100% process transfers Supply Reliability: 99.8% on-time delivery Cost Optimization: 25% average cost reduction

DRAVYOM Competitive Advantages

Pharmaceutical Excellence

Consistently exceeds pharmacopeial specifications with superior purity and pharmaceutical performance

Reliable Supply

Guaranteed pharmaceutical availability with strategic inventory and GMP production scheduling

Development Expertise

Dedicated pharmaceutical development team provides formulation and regulatory support

Regulatory Assurance

Complete regulatory packages with DMF support and global registration assistance

Global Standards

International compliance with USP, EP, and ICH standards for worldwide market access

Partnership Approach

Collaborative relationships with pharmaceutical companies and custom development services